Boston Scientific director granted stock awards
Boston Scientific director Christophe Pierre Weber reported equity-based compensation grants.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Form Type
4
Rhea-AI Filing Summary
Boston Scientific director Christophe Pierre Weber reported equity-based compensation grants. On May 7, 2026, he received 1,140 shares of restricted stock in lieu of 80% of his yearly cash retainer, reflecting a value of approximately $100,000 based on the grant-date closing price.
He also received an annual equity award of 1,767 restricted shares, tied to a program value of $215,000, with $64,500 representing 30% of that award. In addition, he was granted 2,660 Deferred Stock Units, tied to $150,500 (70% of the annual equity award), which convert into common shares after his service on the board ends. All equity awards vest in full at the next annual meeting of stockholders.
Insider Trade Summary
Grant/Award: 5,567 shares
Grant/Award
3 txns
Insider
Weber Christophe Pierre
Role
Director
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Grant/Award | Deferred Stock Units | 2,660 | $0.00 | $0.00 |
| Grant/Award | Common Stock | 1,767 | $0.00 | $0.00 |
| Grant/Award | Common Stock | 1,140 | $0.00 | $0.00 |
Holdings After Transaction:
Deferred Stock Units — 2,660 contracts (Direct);
Common Stock — 3,786 shares (Direct)
Footnotes (4)
- F1. Grant of restricted stock in lieu of 80% yearly cash compensation, vesting in full upon the next annual meeting of stockholders. Reflects a value of approximately $100,000 (representing 80% of the amount of the non-employee director compensation program's cash retainer having a value of $125,000) divided by the closing price of the common stock on the date of grant.
- F2. Annual equity award in the form of restricted stock vesting in full upon the next annual meeting of stockholders. Reflects a value of $215,000 divided by the closing price of common stock on the date of grant. Reflects a value of $64,500 (representing 30% of the amount of the non-employee director compensation program's annual equity award having a value of $215,000) divided by the closing price of common stock on the date of grant.
- F3. Each deferred stock unit represents the Company's commitment to issue one share of Boston Scientific common stock.
- F4. Annual equity award in the form of deferred stock units vesting in full upon the next annual meeting of stockholders. Vested shares of stock will be issued to the reporting person following the reporting person's separation from Board of Director service in accordance with the Company's Non-Employee Director Deferred Compensation Plan. Reflects a value of $150,500 (representing 70% of the non-employee director compensation program's annual equity award having a value of $215,000) divided by the closing price of common stock on the date of grant.
Key Figures
Restricted stock in lieu of cash: 1,140 shares
Annual restricted stock award: 1,767 shares
Deferred Stock Units granted: 2,660 units
+5 more
8 metrics
Restricted stock in lieu of cash
1,140 shares
Grant of restricted stock replacing 80% of yearly cash compensation
Annual restricted stock award
1,767 shares
Annual equity award in restricted stock vesting at next annual meeting
Deferred Stock Units granted
2,660 units
Annual equity award in DSUs vesting at next annual meeting
Cash retainer value
<money>$125,000</money>
Non-employee director cash retainer used to calculate stock in lieu of cash
Restricted stock cash-replacement value
<money>$100,000</money>
80% of yearly cash compensation converted into restricted stock
Annual equity award value
<money>$215,000</money>
Non-employee director annual equity program value
DSU portion of equity award
<money>$150,500</money>
70% of annual equity award delivered as Deferred Stock Units
Restricted stock portion of equity award
<money>$64,500</money>
30% of annual equity award delivered as restricted stock
Key Terms
restricted stock, Deferred Stock Units, Non-Employee Director Deferred Compensation Plan, non-employee director compensation program, +1 more
5 terms
restricted stock financial
"Grant of restricted stock in lieu of 80% yearly cash compensation, vesting in full upon the next annual meeting of stockholders."
Shares granted to an individual that carry limits on transfer or sale until certain conditions are met, such as staying with the company for a set time or hitting performance targets. Think of them as a locked gift that gradually opens; for investors they matter because they affect how many shares may enter the market later, signal management incentives and potential dilution, and reveal confidence in future company performance.
Deferred Stock Units financial
"Each deferred stock unit represents the Company's commitment to issue one share of Boston Scientific common stock."
Deferred stock units are promises from a company to give an employee shares of stock at a future date, often after certain conditions are met or after leaving the company. They function like a form of delayed compensation, allowing employees to earn shares over time. For investors, they represent potential future ownership in the company, but do not provide immediate voting rights or dividends until the shares are actually received.
Non-Employee Director Deferred Compensation Plan financial
"Vested shares of stock will be issued ... in accordance with the Company's Non-Employee Director Deferred Compensation Plan."
non-employee director compensation program financial
"non-employee director compensation program's cash retainer having a value of $125,000"
annual equity award financial
"Annual equity award in the form of deferred stock units vesting in full upon the next annual meeting of stockholders."
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
What did Boston Scientific (BSX) director Christophe Pierre Weber receive in this Form 4 filing?
Christophe Pierre Weber received equity-based compensation, including restricted stock and Deferred Stock Units. The grants replace a portion of his cash retainer and deliver his annual equity award, all structured using Boston Scientific’s non-employee director compensation program and vesting at the next annual stockholder meeting.
What are the Deferred Stock Units reported for Boston Scientific (BSX) director Christophe Pierre Weber?
Weber received 2,660 Deferred Stock Units, each representing a commitment to issue one share of Boston Scientific common stock. These units vest at the next annual meeting, with the actual shares delivered after he leaves the board under the Non-Employee Director Deferred Compensation Plan.
How much compensation value do the Boston Scientific (BSX) equity grants represent for Christophe Pierre Weber?
The restricted stock in lieu of cash reflects about $100,000 of his $125,000 cash retainer. The annual equity program has a value of $215,000, with $64,500 reflected in restricted stock and $150,500 in Deferred Stock Units, all determined using the grant-date closing price.
Do these Boston Scientific (BSX) Form 4 transactions represent market purchases by Christophe Pierre Weber?
No, the transactions are compensation grants, not open-market purchases. The restricted stock and Deferred Stock Units were awarded at a stated value per the non-employee director compensation program, with a grant price of $0.0000 per share rather than cash paid in the market.
When will Christophe Pierre Weber’s Boston Scientific (BSX) equity awards vest and be delivered?
The restricted stock and Deferred Stock Units vest in full upon the next annual meeting of stockholders. Shares underlying the Deferred Stock Units will be issued only after Weber’s separation from board service, following the company’s Non-Employee Director Deferred Compensation Plan provisions.
AI-generated analysis. How Rhea-AI works. Not financial advice.
Accepted by SEC EDGAR
Learn about SEC filing dates